Publications by authors named "Walizeb Khan"

Background: Metabolic reprogramming, particularly glycolysis, is essential in processes like cancer and immune response. While FGF21's role in hepatocyte glucose metabolism has been linked to glucose transporters and its impact on aerobic glycolysis and cellular growth in HCC remain unclear. In this study, we investigated FGF21-mediated modulation of glucose metabolism in HCC through mTOR and HIF1α axis in HCC.

View Article and Find Full Text PDF

Background: Aerobic glycolysis is crucial for cancer cells to survive, grow, and progress. In the current study, the anti-cancer effects of astragalin (ASG) on breast cancer cells and in the glycolytic pathway through AMPK/mTOR have been evaluated.

Objective: The objective of this study was to examine the impact of ASG, a natural flavonoid, on glycolysis via targeting AMPK/mTOR signalling in MDA-MB-231 breast cancer cells.

View Article and Find Full Text PDF

The Fibroblast Growth Factor Receptors (FGFRs) are known to regulate cancer metabolism in different tumor types, including hepatocellular carcinoma (HCC). Several risk factors are associated with HCC, of which viral infections (Hepatitis B and C) and cirrhosis are prominent. In Pakistan as well as in highly developed countries like the United States, hepatitis C virus HCV infections are most commonly reported in HCC.

View Article and Find Full Text PDF

Dysregulated immune response significantly affects hepatocellular carcinoma's (HCC) prognosis. Human Leukocyte Antigens are key in devising immune responses against HCC. Here, we investigated how HLAs modulate HCC development at the transcriptomic level.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the role of fibroblast growth factor receptor 1 (FGFR1) in breast cancer, particularly its connection to endocrine therapy resistance and progression.
  • Researchers analyzed RNA-seq and microarray data from 1,425 breast cancer patients, finding that genes in the SHH pathway are significantly upregulated in FGFR1-positive cases and linked to poor patient outcomes.
  • Combining treatments with FGFR1 inhibitor AZD4547 and GLI1 inhibitor GANT61 not only reduced cancer cell proliferation and invasion but also highlighted the interconnected roles of FGFR1 and GLI1 in breast cancer metastasis, suggesting a potential new therapeutic strategy.
View Article and Find Full Text PDF